Amur Minerals (GB:CRTX) has released an update.
CRISM Therapeutics Corporation has announced a significant stride in cancer treatment with the validation of their ChemoSeed product, a novel drug delivery method for high-grade gliomas. Published in the peer-reviewed journal ‘Cancers,’ the study confirms the safe administration of the chemotherapy drug irinotecan via ChemoSeed directly into the resection margin of glioblastoma patients. This breakthrough is expected to improve survival rates and is set to bolster the company’s upcoming clinical trial application for ChemoSeed.
For further insights into GB:CRTX stock, check out TipRanks’ Stock Analysis page.
